BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37649613)

  • 21. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
    Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
    Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
    Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
    Front Immunol; 2022; 13():942154. PubMed ID: 35936015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
    Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
    Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
    Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
    Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of the expression of FOXP3 and TIGIT in Merkel cell carcinoma.
    Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Matsumoto T; Taniguchi M; Kuwamoto S; Umekita Y; Oda Y
    Sci Rep; 2023 Aug; 13(1):13114. PubMed ID: 37573372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
    Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
    Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
    Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
    Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
    Lupo KB; Yao X; Borde S; Wang J; Torregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; McIntosh M; Matosevic S
    Nat Commun; 2024 Mar; 15(1):1909. PubMed ID: 38429294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
    Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
    PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
    Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 39. Peritumoral TIGIT
    Liu H; Wu J; Xu X; Wang H; Zhang C; Yin S; He Y
    Int Immunopharmacol; 2022 Jul; 108():108735. PubMed ID: 35405596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
    Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
    Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.